30.04.2024,
6536 Zeichen
Zug, Switzerland (ots/PRNewswire) - Medison Pharma ("Medison"), a
global pharma company focused on providing access to highly
innovative therapies for patients in international markets, and
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today a further expansion of their
existing partnership in Central & Eastern Europe and Israel, to also
include selected markets in LATAM and APAC and additional
international markets.
* The expanded partnership will allow Alnylam and Medison to help
accelerate access for patients in multiple regions under one
global alliance
* Medison, the creator and leader of the multi-regional partnership
category, will utilize its unique, unified platform for efficient
global commercialization of Alnylam's innovative RNAi
technologies
Medison, the creator and leader of the multi-regional partnership
category, has established a unique, unified commercialization
platform in international markets, particularly for the treatment of
rare and severe diseases. Medison is the only partner that focuses
solely on the most innovative therapies.
Alnylam and Medison initially partnered in 2018. Ever since, the
partnership has expanded to additional regions and markets, to ensure
that Alnylam's commercial therapies, such as ONPATTRO® (patisiran),
AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO®
(lumasiran) are made available across multiple international markets.
"We are delighted to extend yet again our existing partnership with
Medison, which will enable us to enhance our presence and bring the
benefits of Alnylam's innovative RNAi therapeutics to patients in
additional APAC and LATAM markets," said Norton Oliveira, Senior
Vice-President and Head of Partner and Emerging Markets at Alnylam.
"Medison is at the forefront of the global trend of consolidating
international markets under one alliance. Together, we'll provide
faster access to more patients around the world."
"The new category of the multi-regional partnerships that we have
been creating in the past few years continues to get traction with
the most innovative biotech companies," said Meir Jakobsohn, Founder
and Executive Chairman of Medison. "We are proud of our longstanding
partnership with Alnylam and will continue to work together to bridge
geographical gaps, ensuring that Alnylam's life-saving therapies
reach patients in need."
"Our unified commercial platform enables biotech companies to
transform numerous complex and fragmented markets and regions into a
unified territory, and we are proudly leading the trend and the
category," said Gil Gurfinkel, CEO of Medison. "Our expanding
partnership with Alnylam shows just how our one-of-a-kind unified
commercial platform, with single alliance management across multiple
markets and regions, is of great value to leading biotech companies.
This partnership will make Alnylam's therapies available in
additional international markets, offering newfound hope for patients
suffering from rare diseases."
About RNAi RNAi (RNA interference) is a natural cellular process of
gene silencing that represents one of the most promising and rapidly
advancing frontiers in biology and drug development today. Its
discovery has been heralded as "a major scientific breakthrough that
happens once every decade or so," and was recognized with the award
of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the
natural biological process of RNAi occurring in our cells, a new
class of medicines known as RNAi therapeutics is now a reality. Small
interfering RNA (siRNA), the molecules that mediate RNAi and comprise
Alnylam's RNAi therapeutic platform, function upstream of today's
medicines by potently silencing messenger RNA (mRNA) – the genetic
precursors – that encode for disease-causing or disease pathway
proteins, thus preventing them from being made. This is a
revolutionary approach with the potential to transform the care of
patients with genetic and other diseases.
About Medison Pharma Medison is a global pharma company focused on
providing access to highly innovative therapies to patients in
international markets, with presence in Central and Eastern Europe,
Canada, Latin America, Asia Pacific, Australia and Israel. Medison is
the first to create an international commercialization platform for
highly innovative therapies, helping to save and improve lives by
making the best available novel treatments accessible to patients in
international markets. Medison has a track record of multi-regional
partnerships with leading pharmaceutical and biotech companies
seeking to expand their global reach.
To learn more visit www.medisonpharma.com.
About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY)
has led the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of people afflicted with rare and prevalent diseases with unmet
need. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach yielding
transformative medicines. Since its founding 20 years ago, Alnylam
has led the RNAi Revolution and continues to deliver on a bold vision
to turn scientific possibility into reality. Alnylam's commercial
RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI®
(givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio®
(inclisiran), which is being developed and commercialized by
Alnylam's partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates that
are in late-stage development. Alnylam is executing on its "Alnylam
P5x25" strategy to deliver transformative medicines in both rare and
common diseases benefiting patients around the world through
sustainable innovation and exceptional financial performance,
resulting in a leading biotech profile. Alnylam is headquartered in
Cambridge, MA.
Logo:
https://mma.prnewswire.com/media/2391475/Medison_Pharma_a...
ogo.jpg
Contacts: Medison Pharma Inbal Chen, Corporate Communications
T: +972-54-4400784
E: inbalc@medisonpharma.com
Alnylam Pharmaceuticals Sara Guzzone Fallon, Senior Director, Global
Commercial Communications
T: +1 631 335 1379
E: sfallon@alnylam.com
View original
content:https://www.prnewswire.co.uk/news-releases/medison-pharma-and
-alnylam-pharmaceuticals-announce-expansion-of-their-multi-regional-p
artnership-in-europe-and-israel-to-commercialize-rnai-therapeutics-in
-additional-latam-and-apac-markets-including-australia-302131429.html
Digital press kit:
http://www.ots.at/pressemappe/PR168967/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Wiener Börse Party #652: Semperit feiert in der Börse, wer feiert mit mir? ATX TR zum Mai-Verfall auf Kurs 6. All-time-High heuer
Aktien auf dem Radar:FACC, Rosenbauer, AT&S, Amag, Flughafen Wien, Frequentis, Addiko Bank, Rosgix, Palfinger, Pierer Mobility, Erste Group, Österreichische Post, Marinomed Biotech, Gurktaler AG Stamm, Polytec Group, S Immo, Agrana, CA Immo, EVN, Immofinanz, Kapsch TrafficCom, OMV, Telekom Austria, Uniqa, VIG, Wienerberger, Siemens, BMW, Sartorius, DAIMLER TRUCK HLD..., Wal-Mart.
UBM
Die UBM fokussiert sich auf Immobilienentwicklung und deckt die gesamte Wertschöpfungskette von Umwidmung und Baugenehmigung über Planung, Marketing und Bauabwicklung bis zum Verkauf ab. Der Fokus liegt dabei auf den Märkten Österreich, Deutschland und Polen sowie auf den Asset-Klassen Wohnen, Hotel und Büro.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER